Yu Qian, Shi Yuchen, Wu Yuehong, Liu Ruifei, Zhang Hui, Wu Lingling, Ding Mingxing
Medical Molecular Biology Laboratory, School of Medicine, Jinhua Polytechnic, Jinhua, Zhejiang 321017, P.R. China.
Department of Psychiatry, Jinhua Second Hospital, Jinhua, Zhejiang 321016, P.R. China.
Exp Ther Med. 2024 Nov 14;29(1):12. doi: 10.3892/etm.2024.12762. eCollection 2025 Jan.
Magnolol may have the potential to alleviate the progression of Alzheimer's disease (AD). The present study was conducted to investigate the broader mechanism of action of magnolol in AD pathogenesis. C57BL/6 mice were randomly divided into five groups (n=6 mice/group): i) Control; ii) AD model; iii) 5 mg/kg magnolol + AD model; iv) 10 mg/kg magnolol + AD model; and v) 20 mg/kg magnolol + AD model. A total of 7 days after modeling, the treatment groups were administered different doses of magnolol (5, 10 and 20 mg/kg) by gavage every day, and a Morris water maze test was conducted after 2 months of treatment. The impacts of magnolol on amyloid β (Aβ) plaque deposition and neuroinflammation were assessed using Congo red and immunofluorescence staining. Immunofluorescence staining results were supplemented with western blotting and reverse transcription-quantitative PCR to ascertain the role of magnolol in other pivotal pathological mechanisms, including the formation of intracellular neurofibrillary tangles, compromised synaptic plasticity, and astrocyte and microglia activation. Administration of magnolol effectively mitigated cognitive impairment, reduced Aβ plaque deposition and inhibited neuroinflammation in Aβ-induced mice. Moreover, hippocampal levels of tau, phosphorylated (p-)tau, glycogen synthase kinase 3β (GSK3β), p-GSK3β, synaptophysin, brain-derived neurotrophic factor, glial fibrillary acidic protein and ionized calcium binding adaptor molecule 1 revealed that magnolol also limited neurofibrillary tangle formation, repaired synaptic plasticity, and inhibited astrocyte and microglia activation. In conclusion, the present findings broaden the current understanding of the mechanisms explaining the neuroprotective effects of magnolol against AD progression. Notably, it may inhibit multiple manifestations of AD, including plaques and neuroinflammation, while also exhibiting the capacity to restore AD-related neurological damage.
厚朴酚可能具有缓解阿尔茨海默病(AD)进展的潜力。本研究旨在探讨厚朴酚在AD发病机制中的更广泛作用机制。将C57BL/6小鼠随机分为五组(每组n = 6只小鼠):i)对照组;ii)AD模型组;iii)5 mg/kg厚朴酚 + AD模型组;iv)10 mg/kg厚朴酚 + AD模型组;v)20 mg/kg厚朴酚 + AD模型组。建模后7天,治疗组每天通过灌胃给予不同剂量的厚朴酚(5、10和20 mg/kg),治疗2个月后进行莫里斯水迷宫试验。使用刚果红和免疫荧光染色评估厚朴酚对淀粉样β(Aβ)斑块沉积和神经炎症的影响。免疫荧光染色结果辅以蛋白质印迹法和逆转录-定量PCR,以确定厚朴酚在其他关键病理机制中的作用,包括细胞内神经原纤维缠结的形成、突触可塑性受损以及星形胶质细胞和小胶质细胞活化。给予厚朴酚可有效减轻Aβ诱导小鼠的认知障碍,减少Aβ斑块沉积并抑制神经炎症。此外,海马中tau、磷酸化(p-)tau、糖原合酶激酶3β(GSK3β)、p-GSK3β、突触素、脑源性神经营养因子、胶质纤维酸性蛋白和离子钙结合衔接分子1的水平表明,厚朴酚还可限制神经原纤维缠结的形成,修复突触可塑性,并抑制星形胶质细胞和小胶质细胞活化。总之,本研究结果拓宽了目前对厚朴酚抗AD进展神经保护作用机制的认识。值得注意的是,它可能抑制AD的多种表现,包括斑块和神经炎症,同时还具有恢复AD相关神经损伤的能力。